HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer

Molecular Cancer Therapeutics

Volumn 11, Issue 4, 2012, Pages 830-841

  Minami, Toshiyuki ^a   Kijima, Takashi ^a   Otani, Yasushi ^a   Kohmo, Satoshi ^a   Takahashi, Ryo ^a   Nagatomo, Izumi ^a   Hirata, Haruhiko ^a   Suzuki, Mayumi ^a   Inoue, Koji ^a   Takeda, Yoshito ^a   Kida, Hiroshi ^a   Tachibana, Isao ^a   Kumanogoh, Atsushi ^a,b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FIRTECAN; IRINOTECAN; LAPATINIB; MULTIDRUG RESISTANCE PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; LUNG SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; QUINAZOLINES; RECEPTOR, ERBB-2; SMALL CELL LUNG CARCINOMA; TRANSFECTION; UP-REGULATION;

EID: 84862727610     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0884     Document Type: Article

References (47)

1. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355:479-85. (Pubitemid 30085163)
2. Hanna NH, Einhorn LH. Small-cell lung cancer: state of the art. Clin Lung Cancer 2002;4:87-94. (Pubitemid 35174865)
3. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91. (Pubitemid 34438898)
4. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32. (Pubitemid 41058344)
6. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
7. Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 2005;49:337-43. (Pubitemid 41139146)
8. Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, et al. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005;65:1541-6. (Pubitemid 40270183)
9. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamilyGmember 2-mediated drug resistance. Cancer Res 2007;67:11012-20. (Pubitemid 350145931)
10. Ménard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000;182:150-62. (Pubitemid 30022667)
11. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12. (Pubitemid 19147683)
12. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413-28. (Pubitemid 28524507)
13. Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009;35:121-36.
14. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008;68:7905-14.
15. Micke P, Hengstler JG, Ros R, Bittinger F, Metz T, Gebhard S, et al. cerbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer 2001;92:474-9. (Pubitemid 32319418)
16. Potti A, Willardson J, Forseen C, Kishor Ganti A, Koch M, Hebert B, et al. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer 2002;36:257-61. (Pubitemid 34497123)
17. Liu L, Shao X, Gao W, Bai J, Wang R, Huang P, et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 2010;5:1922-32.
18. Miyamoto H. Establishment and characterization of an adriamycin-resistant subline of human small cell lung cancer cells. Acta Med Okayama 1986;40:65-73. (Pubitemid 17173391)
19. Moritaka T, Kiura K, Ueoka H, Tabata M, Segawa Y, Shibayama T, et al. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids. Anticancer Res 1998;18:927-33. (Pubitemid 28239618)
20. Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Kimura I. Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. Acta Med Okayama 1992;46:203-12.
21. Chikamori M, Takigawa N, Kiura K, Tabata M, Shibayama T, Segawa Y, et al. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line. Anticancer Res 2004;24:3911-6. (Pubitemid 40468685)
22. Mitsuhashi Y, Inaba M, Sugiyama Y, Kobayashi T. In vitro measurement of chemosensitivity of human small cell lung and gastric cancer cell lines toward cell cycle phase-nonspecific agents under the clinically equivalent area under the curve. Cancer 1992;70:2540-6.
23. Hong WS, Saijo N, Sasaki Y, Minato K, Nakano H, Nakagawa K, et al. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int J Cancer 1988;41:462-7. (Pubitemid 18080806)
24. Minato K, Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y, Saijo N. Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother Pharmacol 1990;26:313-7. (Pubitemid 20271531)
25. Tanio Y, Watanabe M, Osaki T, Tachibana I, Kawase I, Kuritani T, et al. High sensitivity to peripheral blood lymphocytes and low HLA-class I antigen expression of small cell lung cancer cell lines with diverse chemo-radiosensitivity. Jpn J Cancer Res 1992;83:736-45.
26. Ishiyama M, Miyazono Y, Sasamoto K, Ohkura Y, Ueno K. A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 1997;44:1299-305. (Pubitemid 27249311)
27. Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 1994;46:627-38. (Pubitemid 24334752)
28. Wierdl M, Wall A, Morton CL, Sampath J, Danks MK, Schuetz JD, et al. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance. Mol Pharmacol 2003;64:279-88. (Pubitemid 36909991)
29. Chu QS, Schwartz G, de Bono J, Smith DA, Koch KM, Versola MJ, et al. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. J Clin Oncol 2007;25:3753-8. (Pubitemid 47372617)
30. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59. (Pubitemid 47050835)
31. Cai C, Chen J. Overexpression of caveolin-1 induces alteration of multidrug resistance in Hs578T breast adenocarcinoma cells. Int J Cancer 2004;111:522-9. (Pubitemid 39045318)
32. Barakat S, Demeule M, Pilorget A, Regina A, Gingras D, Baggetto LG, et al. Modulation of p-glycoprotein function by caveolin-1 phosphorylation. J Neurochem 2007;101:1-8. (Pubitemid 46426486)
33. Bunn PA Jr, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 2001;7:3239-50. (Pubitemid 32963849)
34. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46. (Pubitemid 40425952)
35. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003;9:5880-7. (Pubitemid 38018071)
36. Moore AM, Einhorn LH, Estes D, Govindan R, Axelson J, Vinson J, et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006;52:93-7. (Pubitemid 43340205)
37. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004;65:1485-95. (Pubitemid 38668306)
38. Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3- fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino} methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008;36:695-701. (Pubitemid 351468376)
39. Brozik A, Hegedus C, Erdei Z, Hegedus T, Ozvegy-Laczka C, Szakacs G, et al. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol 2011;7:623-42.
40. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 1997;272:30429-38. (Pubitemid 27512253)
41. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, et al. Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 1998;273:20448-55. (Pubitemid 28377612)
42. Hawkins BT, Sykes DB, Miller DS. Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci 2010;30:1417-25.
43. Seute T, Leffers P, Wilmink JT, ten Velde GP, Twijnstra A. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 2006;24:2079-83. (Pubitemid 46622118)
44. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM,Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product Pglycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987;84:7735-8.
45. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2- (methylsulfonyl)ethy l]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 2009;37:439-42.
46. Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer 2004;45 Suppl 2:S253-7. (Pubitemid 39488196)
47. Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res 2012;29:770-81.